Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at Zacks Research

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports.

A number of other brokerages also recently issued reports on ZLDPF. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Get Zealand Pharma A/S alerts:

Read Our Latest Report on Zealand Pharma A/S

Zealand Pharma A/S Stock Performance

ZLDPF opened at $34.87 on Monday. The firm has a fifty day moving average price of $45.33 and a 200 day moving average price of $46.13. Zealand Pharma A/S has a 1 year low of $34.87 and a 1 year high of $83.12. The stock has a market cap of $2.49 billion, a P/E ratio of 5.78 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.

Featured Stories

• Five stocks we like better than Zealand Pharma A/S
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.